MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.3 USD | -0.59% |
|
+1.35% | +18.59% |
| 13/05 | Merck: phase 3 trial in melanoma halted | CF |
| 13/05 | Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study | DJ |
ETFs positioned on Merck & Co., Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.33% | 34 M€ | +8.24% | - | |
| 0.33% | 4 M€ | -.--% | - | |
| 0.32% | 36 M€ | +2.47% | - | |
| 0.32% | 23 M€ | +7.25% | - | |
| 0.32% | 35 M€ | +8.15% | - | |
| 0.30% | 169 M€ | -0.77% | - | |
| 0.25% | 26 M€ | +16.85% | - | |
| 0.24% | 306 M€ | +5.68% | - | |
| 0.24% | 39 M€ | +5.65% | - | |
| 0.24% | 12 M€ | +11.92% | - | |
| 0.23% | 17 M€ | +4.26% | - | |
| 0.23% | 20 M€ | +1.59% | - | |
| 0.21% | 7 M€ | +5.61% | - | |
| 0.21% | 32 M€ | +1.38% | - | |
| 0.21% | 17 M€ | +5.61% | - | |
| 0.19% | 105 M€ | +3.54% | - | |
| 0.17% | 6 M€ | +3.89% | ||
| 0.16% | 17 M€ | +2.80% | - | |
| 0.11% | 2 M€ | +3.16% | - | |
| 0.10% | 54 M€ | +0.54% | - |
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
16/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
129.3
USD
Average target price
141.6
USD
Spread / Average Target
+9.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.59% | 33TCr | |
| +29.98% | 68TCr | |
| +30.34% | 57TCr | |
| -3.52% | 36TCr | |
| +4.07% | 28TCr | |
| +16.21% | 24TCr | |
| +9.66% | 21TCr | |
| -6.83% | 20TCr | |
| +7.09% | 17TCr | |
| -1.22% | 16TCr |
- Stock Market
- Equities
- MRK Stock
- Funds and ETFs Merck & Co., Inc.